← Leaderboards
Amol Anant Kulkarni
Howard University
$454,061
Attributed
$908,121
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $263.1K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$908,121 · 2
By mechanism
R21$908,121 · 2
Top collaborators
- Michael Ilya Bukrinsky5 shared
Others in their field
Other Rising Stars on “Drug Discovery”
- Gene Garrard Olinger · University Of Texas Med Br Galveston$23,000,000
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Taleen Hanania · Psychogenics, Inc.$9,482,040
Research focus
Drug DiscoveryFunctional DisorderComputer StudiesDrug DesignExploratory/Developmental GrantFoundationsClinical ResearchComputer-Aided DesignAreaCytokineAntiretroviral TherapyDruggable TargetAnalogBindingAffectBiologicalComorbidityBrainCasp1 GeneCell LineCessation Of LifeAstrocytesChronicFuture
Grant awards (5)
Development of NLRP3 inhibitors for HIV-associated neuroinflammation in cocaine use.$196,876
R21 · FY2025 · DA · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation in cocaine use.$263,119
R21 · FY2024 · DA · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$156,884
R21 · FY2023 · NS
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$79,242
R21 · FY2023 · NS · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$212,000
R21 · FY2022 · NS · contact PI